Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04206969
Other study ID # P180601
Secondary ID 2019-A01830-57
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date April 2020
Est. completion date October 2023

Study information

Verified date December 2019
Source Assistance Publique - Hôpitaux de Paris
Contact Jonathan LACHAL, PhD
Phone 00331 58 41 28 14
Email jonathan.lachal@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The symptomatic and clinical expression of psychiatric disorders in children and adolescents is strongly influenced by the cultural setting they are growing up in. These cultural variations complicate psychiatric care, especially for migrant children, for whom appropriate care must be designed.

Transcultural psychotherapy is an original psychotherapeutic technique developed to meet these specific requirements in France and in different European and American countries. Its theoretical and methodological foundations rest on the works of George Devereux in ethnopsychiatry (1970). A psychotherapeutic technique intended for first-generation migrants was developed by Tobie Nathan and coll (1986). Marie-Rose Moro and colleagues (1990) have adapted this technique to second-generation migrants.

Indicated as a second-line treatment after the failure of standard management, this technique is fully formalized today. It comprises group consultations for the child and the family as a one-hour session each month, directed by a principal therapist, assisted by a group of co-therapists (of diverse cultural origins and occupations) and an interpreter in the family's mother tongue. The concept of culture is used to establish the therapeutic alliance, decode the symptoms, and propose treatment.

The children and adolescents receiving this treatment have varied psychopathological profiles, mostly involving depressive and/or anxiety disorders. Specifically, migrants' children are especially vulnerable to depression, their psychiatric care is generally longer and less effective than in the general population, and their rate of treatment failure higher.

Transcultural psychotherapy has demonstrated its value in these situations in numerous qualitative studies, but its efficacy has not yet been assessed by a method providing a high level of evidence, such as randomized controlled trials.


Description:

Mixed method study using a multicenter, Bayesian randomized clinical trial with blinded evaluation of the primary outcome. Two parallel groups of 40 children or adolescents from 6 to 20 years-old and their family will be included. In the experimental group, patients will attend six sessions of transcultural therapy in addition to usual care. The improved Clinical Global Impression scale scores at 6 months will be compared across groups. Qualitative analysis of families and therapists' interviews will allow to specify the therapeutic processes and acceptability of the therapy.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 80
Est. completion date October 2023
Est. primary completion date October 2022
Accepts healthy volunteers No
Gender All
Age group 6 Years to 20 Years
Eligibility Inclusion Criteria:

- Be a child aged or an adolescent aged 6-20 years-old (this may be a declaratory age at the time of the consultation or based on a document for a residence request if no other identity documents are available)

- Be a first or second-generation migrant (born abroad or born from at least one parent who is born abroad)

- Have a psychological and/or psychiatric follow-up by a first-line care

- Have been referred for transcultural psychotherapy by their first line care to treat depression resistant to standard management.

- Present a depression according to the clinician who proposes the transcultural treatment (first line therapist), based on usual as well as cultural symptoms criteria of the below list:

- Sadness

- Diminish interest or pleasure in most of the usual activities

- Insomnia or hypersomnia

- Psychomotor agitation

- Asthenia, loss of energy

- Feeling of worthlessness or excessive guilt

- Recurrent throughs of death

- School problems (school failure, drop in grades, aggressivity with adult, school refusal…)

- Mutism, and selective mutism

- Runaways

- Aggressivity

- Impulsivity

- Violence and delinquency

- Conflicts with parents and adults from the community

- Exclusion from family

- Somatic pains

- Massive separation anxiety

- Regressive symptoms - loosing of an already acquired function such as speech, walk, stay alone for a sufficient time in relation to age, manage stress or anxiety for reasonable situations…

- Denial of medical care for a chronic disease with no evident reasons

- Cultural designation such as possessed by a spirit, being a child witch, or other cultural designations

- State of trance The list is not exhaustive, and some other symptoms may be accepted if the first line clinician as well as the referent agree. The patients will be well characterized after inclusion.

- Present a score >= 4 on the iCGI - Severity at inclusion.

- Present transcultural issues confirmed by the referent (usual procedure of indirect pre-selection based on the presentation of the situation by referring physician)

- Have an informed consent signed by both parents/ one parent / tutor / adult patient (cf. 14.1 paragraph)

Exclusion Criteria:

- Patient or family has previously had transcultural psychotherapy

- Patient presents an acute psychiatric disorder which hinders the realization of the transcultural therapy - for example, excited delirium with great psychic disorganization, or high suicidal risk patients. These situations will be excluded during the screening time based on the first line therapist evaluation

- Patient presents an acute somatic disease which may hinder the well organization of the therapy

- Patient addressed for a legal expertise

- Child's/Adolescent's refusal

- Pregnant or breastfeeding (for women for young women of childbearing age)

- Participation in another interventional study

- Patient under guardianship or curatorship

Study Design


Intervention

Behavioral:
Transcultural psychotherapy
In addition to usual care, the participants receive transcultural psychotherapy

Locations

Country Name City State
France Service de Psychopathologie de l'enfant, de l'adolescent, CHU Avicenne Bobigny
France Service de médecine interne, unité de consultation transculturelle, CHRU Saint-André (CHU Bordeaux) Bordeaux
France Service de psychiatrie de l'enfant et de l'adolescent, CHRU Gabriel Montpied Clermont-Ferrand
France Maison de Solenn, Cochin Hospital Paris
France Secteur 75G23, Centre Médico-psychologique (CMP), GHU PARIS, Maison blanche Paris
France Centre Médico-psychologique, Service Universitaire de Psychiatrie de l'Enfant et de l'Adolescent, Hôpital La Grave, CHU Toulouse Toulouse

Sponsors (2)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris Institut National de la Santé Et de la Recherche Médicale, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Severity Score on the Improved Global Impression Scale (iCGI) to assess remission .iCGI score is a scale ranging from 1 to 7, 1 being Normal, not at all ill, and 7 - Among the most extremely ill patients.
- Normal, not at all ill
- Borderline mentally ill
- Mildly ill
- Moderately ill
- Markedly ill
- Severely ill
- Among the most extremely ill patients
Remission is defined as a mean iCGI score over the 3 experts <4 at 28 weeks of treatment (W34).
at week 34 visit (v5)
Secondary Severity score on the iCGI To compare the course of the severity of depression in each group over the first 34 weeks after inclusion at baseline and weeks 6, 13, 20, 27 and 34 and 52
Secondary Score on the French version of the Children's Depression Rating Scale-Revised (CDRS-R) It's a 17-item scale with answers on 5 or 7-point Likert scale (total score ranges from 17 to 113). A score = 40 is indicative of depression, whereas a score =28 is often used to define remission.
To compare the course of the level of depressive symptoms in each group over the first 34 weeks after inclusion
at baseline and weeks 6, 13, 20, 27 and 34 and 52
Secondary Score on the French version of the State-Trait Anxiety Inventory for children (STAI-C) To compare the course of the level of anxiety symptoms in each group over the first 34 weeks after inclusion at baseline and weeks 6, 13, 20, 27 and 34 and 52
Secondary Score changes in Depression and anxiety Scores between Week 34 and week 52 To evaluate the persistence of the efficacy of transcultural psychiatry over time by describing the course of the severity of the depression and of the depressive and anxiety symptoms from 34 to 52 weeks after inclusion in the group of patients treated by transcultural psychotherapy during the first 34 weeks at 34 and 52 weeks
Secondary analysis of the content of the clinical data collected during the visits To describe the therapeutic processes that enabled the improvement of patients treated by transcultural psychotherapy between 34 and 44 weeks
Secondary analysis of the content of the interview with the families and therapists at the end of the treatment For this secondary objective concerning the group of patients treated by transcultural psychotherapy, a qualitative design will be used to explore the perceived efficacity and acceptability of the therapy. Investigators will organize two semi-structured interviews after the fifth therapy session. These semi-structured interviews will be conducted by a psychologist trained in transcultural care. One interview will concern the family and will explore, with the help of an interpreter speaking the native language of the family, the acceptability of the care as well as success factors identified by the family. The other interview will concern the therapists and will explore the success factors identified by the professionals. The interviews guides have been constructed by specialists of transcultural care in childhood and adolescence To describe the perceived efficacy and acceptability of the transcultural psychotherapy for the patient and the family between 34 and 44 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05537558 - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Completed NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Recruiting NCT05547035 - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders N/A
Terminated NCT02940769 - Neurobiological Effects of Light on MDD N/A
Recruiting NCT05892744 - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression Phase 4
Recruiting NCT05537584 - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Phase 4
Active, not recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Completed NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Recruiting NCT05527951 - Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study N/A
Completed NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT05895747 - 5-HTP and Creatine for Depression R33 Phase Phase 2
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Recruiting NCT05813093 - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression N/A
Recruiting NCT05135897 - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT06026917 - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Phase 4
Recruiting NCT06145594 - EMA-Guided Maintenance TMS for Depression N/A